As of May 28, 2020, all 50 states, Washington D.C., and certain U.S. Territories have successfully verified COVID-19 diagnostic tests and are offered by over 245 testing services.
To date, 113 Emergency Use Authorizations (EUA), which includes 100 molecular tests, 12 antibody tests, and 1 antigen test, have been issued by the FDA for diagnostic tests under the policies set forth in the COVID-19 Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency Guidance. A EUA allows the agency to make available unauthorized treatments or diagnostics, based on a review of limited data, during a public health emergency.
The US Centers for Disease Control and Prevention (CDC) issued Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings on May 23, 2020.
"Serologic test results should not be used to make decisions about grouping persons residing in or being admitted to congregate settings, such as schools, dormitories, or correctional facilities," the CDC says. Across local populations, testing produces more accurate results if the disease being tested for is common in the population. If an infection has only affected a small percentage of people being tested, even a very small margin of error in a test will be magnified.
The higher the test sensitivity, the fewer false negatives a test will give. The higher the specificity, the fewer false positives.
If you think you have coronavirus disease 2019 (COVID-19) and need a test, contact your healthcare provider immediately. Or, contact your local health department regarding questions about testing. The FDA issued the Coronavirus Testing Basics to provide information about the different types of tests available and the steps involved in obtaining results.
- Diagnostic testing for SARS-CoV-2 is currently performed by a healthcare professional. The test analyzes the qualitative detection of nucleic acid from the COVID-19 disease in upper and lower respiratory specimens such as nasal swabs, throat swabs, and if possible sputum collected from individuals who meet 2019-nCoV clinical and/or epidemiological criteria.
- Nucleic acid amplification tests," or "NAAT" tests are molecular tests that detect the virus's genetic material collected from the patient. These FDA-authorized NAAT tests for SARS-CoV-2 based on the currently available data, we believe are highly accurate. This means that a positive or a negative result from a NAAT test is likely to be true.
- Serologic assays for the SARS-CoV-2 coronavirus now have Emergency Use Authorization by the FDA. Currently, there is no identified advantage of assays whether they test for IgG, IgM, and IgG, or total antibody, says the CDC.
- The FDA recommends that healthcare providers continue to use serological tests intended to detect antibodies to SARS-CoV-2 to help identify people who may have been exposed to the SARS-CoV-2 virus or have recovered from the COVID-19 infection. Health care providers should also be aware of the limitations of these tests and the risks to patients and the community if the test results are used as the sole basis to diagnose COVID-19 disease.
- Serological/antibody tests have been validated for the diagnosis of SARS-CoV-2 infection. Antibody testing is an important next step to tell if someone has been previously infected. It will provide more understanding of the virus, including how long antibodies stay in the body and if they provide immunity.
- The serology or antibody test measures the number of antibodies present in the blood when the body is responding to a specific infection, like SARS-CoV-2. This means the test detects the body's immune response to the infection caused by the virus rather than detecting the virus itself. In the early days of an infection when the body's immune response is still building, antibodies may not be detected.
- Serological tests can play a critical role in the fight against COVID-19 disease by helping healthcare professionals to identify individuals who have overcome infection in the past and have developed an immune response.
Tests Now FDA Approved For Patient Care Settings
- Quest COVID-19 Antibody Test
- LabCorp COVID-19 at-home collection test kit
- Abbott Diagnostics Scarborough, Inc: ID NOW COVID-19
- Mesa Biotech Inc: Accula SARS-Cov-2 Test
- Cepheid: Xpert Xpress SARS-CoV-2 test
- Roche’s SARS-CoV2 antibody test
Note: The FDA's COVID-19 Industry Hotline (1-888-INFO-FDA, press *) addresses questions on topics such as diagnostic testing.
May 2020 Coronavirus Diagnostic Development News
- May 23, 2020 - Interim Guidelines for COVID-19 Antibody Testing issued bu the US CDC. "It cannot be assumed that individuals with truly positive antibody test results are protected from future infection," the CDC says in the updated guidelines. "Serologic testing should not be used to determine immune status in individuals until the presence, durability, and duration of immunity is established."
- May 21, 2020 - Abbott announced today an interim analysis of an ongoing multi-site clinical study in urgent care clinics that indicates its ID NOW COVID-19 rapid test is showing strong agreement to lab-based molecular polymerase chain reaction (PCR) instruments. The interim results are demonstrating ID NOW COVID-19 test performance is ≥94.7% in positive agreement (sensitivity) and ≥98.6% negative agreement (specificity) when compared to two different lab-based PCR reference methods.
- May 20, 2020 - GlaxoSmithKline’s consumer health unit announced an agreement with Mammoth Biosciences to develop a test that uses a technology commonly used in gene editing to detect novel coronavirus infections, reported Reuters. The test will use Mammoth’s CRISPR-based platform to identify the presence of viral RNA strands through a nasal swab and deliver results in less than 20 minutes, Mammoth said.
- May 20, 2020 - Walmart and Quest Diagnostics announced that 7 Walmart stores across the state of New Jersey will open COVID-19 drive-thru testing sites beginning on May 22, 2020. The testing sites, which are supported by NJ state and local officials, will test adults who meet the testing criteria on who should be tested, including first responders, healthcare providers, and others with symptoms of COVID-19, and those in high-risk groups without symptoms.
- May 15, 2020 - The U.S. FDA issued a EUA to Everlywell, Inc. for the Everlywell COVID-19 Test Home Collection Kit. Everlywell’s kit is authorized to be used by individuals at home who have been screened using an online questionnaire that is reviewed by a health care provider. This allows an individual to self-collect a nasal sample at home using Everlywell’s authorized kit.
- May 14, 2020 - The U.S. FDA is alerting the public to early data that suggest potential inaccurate results from using the Abbott ID NOW point-of-care test to diagnose COVID-19. Specifically, the test may return false-negative results.
- May 12, 2020 - LabCorp announced that its COVID-19 at-home collection test kit is now being offered to individuals nationwide who have symptoms consistent with COVID-19 infection and individuals without symptoms who may have been exposed to the virus.
- May 11, 2020 - Abbott announced that the U.S. FDA issued Emergency Use Authorization for the company's SARS-CoV-2 IgG lab-based serology blood test on the Alinity™ i system. Abbott plans to ship nearly 30 million antibody tests globally in May across its ARCHITECT® and Alinity i™ platforms and will have the capacity for 60 million tests in June 2020.
- May 9, 2020 - FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients. The EUA was issued late Friday to Quidel Corporation for the Sofia 2 SARS Antigen FIA.
- May 8, 2020 - The U.S. FDA authorized the 1st diagnostic test with the option of using home-collected saliva samples for COVID-19 disease testing. Specifically, the FDA issued an emergency use authorization to Rutgers Clinical Genomics Laboratory for their COVID-19 laboratory-developed test. The new at-home saliva self-collection assay, developed by RUCDR in partnership with Spectrum Solutions and Accurate Diagnostic Labs, allows for broader screening than through the standard method using nose and throat swabs at testing locations requiring physical interactions with a healthcare professional.
- May 5, 2020 - CRISPR-based research tool delivers results in an hour; researchers share protocol and kits to advance research and move toward clinical validation. A team of researchers at the McGovern Institute for Brain Research at MIT, the Broad Institute of MIT and Harvard, the Ragon Institute, and the Howard Hughes Medical Institute (HHMI) has developed a new diagnostics platform called STOP (SHERLOCK Testing in One Pot).
- May 4, 2020 - Insight into FDA’s Revised Policy on Antibody Tests: Prioritizing Access and Accuracy.
- May 3, 2020 - Roche announced it's COVID-19 antibody test received FDA EUA and is available in markets accepting the CE mark. Roche’s SARS-CoV2 antibody test, which has a specificity greater than 99.8% and 100% sensitivity3 (14 Days post-PCR confirmation), can help assess patients’ immune response to the virus. As more is understood about immunity to SARS-CoV-2, the test may help to assess who has built up immunity to the virus.
April 2020 Coronavirus Diagnostic Development News
April 28, 2020 - Quest Diagnostics announced individuals can purchase COVID-19 antibody testing for themselves, online, without visiting a doctor's office.
April 26, 2020 - FDA issued to Abbott Laboratories Inc. a new EUA for the SARS-CoV-2 IgG assay.
April 22, 2020 - Quest Diagnostics the world's leading provider of diagnostic information services announced that it has begun to perform antibody testing for coronavirus (COVID-19) using blood samples. With the new service, Quest Diagnostics now provides healthcare providers in the USA access to COVID-19 antibody as well as molecular diagnostic laboratory testing.
April 21, 2020 - The FDA re-issued the EUA for the Laboratory Corporation of America (LabCorp) COVID-19 RT-PCR Test to permit testing of samples self-collected by patients at home using LabCorp’s Pixel by LabCorp COVID-19 Test home collection kit.
April 16, 2020 - Paris based Sanofi and Luminostics have signed an agreement to evaluate a collaboration on a unique self-testing solution for COVID-19. The goal of this collaboration is to provide a consumer-based test that can detect the COVID-19 virus with high sensitivity and specificity from respiratory samples. The total time from specimen collection to results is expected in the range of 30 minutes or less. It is based on Luminostics' unique technology that utilizes a consumer smartphone's optics, controlled by an iOS/Android app paired with an inexpensive adapter, in combination with "glow-in-the-dark" nanochemistry and signal processing artificial intelligence.
April 15, 2020 - Abbott announced the launch of its third COVID-19 test, a lab-based serology blood test for the detection of the antibody, IgG, that identifies if a person has had the novel coronavirus SARS-CoV-2.
April 14, 2020 - The U.S. FDA announced it granted Emergency Use Authorization to Ortho Clinical Diagnostics’ total antibody assay for COVID-19—the VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and Calibrators. The VITROS Systems, already installed in more than 1,000 hospitals and reference labs in the U.S., are self-contained and do not require an external water source to run, offering labs placement flexibility.
April 13, 2020 - The U.S. FDA has granted emergency use authorization to Rutgers’ RUCDR Infinite Biologics and its collaborators, for a new collection approach that utilizes saliva as the primary test biomaterial for the SARS-CoV-2 coronavirus. This is the first such approval granted by the FDA.
April 11, 2020 - CMS together with the Departments of Labor and the Treasury, issued guidance to ensure Americans with private health insurance have coverage of 2019 Novel Coronavirus (COVID-19) diagnostic testing and certain other related services, including antibody testing.
April 9, 2020- FirstWave Bio, Inc., announced plans to initiate a Phase 2a/2b study with FW-1022 in patients with COVID-19, beginning in mid-2020. With insights emerging into the crucial role of the gastrointestinal (GI) tract in COVID-19 severity and transmission, the company is accelerating the clinical development of FW-1022 to meet the urgent need for new strategies to combat the virus. FW-1022 is a proprietary oral formulation of Niclosamide, an FDA-approved anthelminthic drug with broad-spectrum antiviral properties that is currently listed on the WHO’s list of essential medicines.
- April 7, 2020 - The FDA said 'In the early days of an infection when the body’s immune response is still building, antibodies may not be detected. This is why tests that detect the body’s immune response should not be used as the sole basis to diagnose COVID-19 disease.
- April 4, 2020 - The CDC's COVIDView weekly reported the national percentage of respiratory specimens testing positive for the SARS-CoV-2 coronavirus is an increasing trend and is now: 16.5% at public health laboratories and, 8.8% at clinical laboratories.
- April 3, 2020 - Ortho Clinical Diagnostics announced it is launching to market its SARS-CoV-2 (COVID-19/coronavirus) antibody test—the VITROS® Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack. Testing kits are expected to be available in a few weeks.
- April 3, 2020 – The Eurofins’ U.S. Clinical Diagnostics network announced today that blood-based antibody testing for Coronavirus SARS-CoV-2 will begin Monday, April 6 at Boston Heart Diagnostics.
- April 2, 2020 - Siemens Healthineers announced the availability of its molecular Fast Track Diagnostics SARS-CoV-2 Assay test kit used to aid in the diagnosis of infection by the SARS-CoV-2 virus that causes the COVID-19 disease. Test kits are already being shipped within the European Union for research use only to expedite availability while the company continues to pursue Emergency Use Assessment and Listing from the WHO for clinical use.
- April 1, 2020 - Aytu BioScience, Inc. announced that it has received its first Coronavirus Disease 2019 IgG/IgM Rapid Test shipment containing 100,000 tests from the manufacturer. The Company is now in the process of relabeling the test kits to comply with FDA requirements relating to the labeling of COVID-19 serology test kits and expects to begin filling current orders shortly thereafter.
- April 1, 2020 - The US FDA issued an approval letter to Cellex for the first blood test that looks for antibodies against the novel coronavirus SARS-CoV-2 that causes COVID-19. This is different than assays that test for the presence of the virus.
March Coronavirus Diagnostic Development News
March 30, 2020 - CMS announced it will allow hospitals, laboratories, and other entities to perform tests for COVID-19 on people at home and in other community-based settings outside of the hospital. This will both increase access to testing and reduce risks of exposure. The new guidance allows healthcare systems, hospitals, and communities to set up testing sites exclusively for the purpose of identifying COVID-19-positive patients in a safe environment.
March 27, 2020 - Abbott announced that the U.S. FDA has issued Emergency Use Authorization for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as 5-minutes and negative results in 13-minutes. The test will run on the company's ID NOW™ platform, providing rapid results in a wide range of healthcare settings such as physicians' offices, urgent care clinics, and hospital emergency departments.
Mar. 26, 2020-- Henry Schein, Inc. announced the availability of an antibody rapid blood test, known as Standard Q COVID-19 IgM/IgG Rapid Test, intended to be administered at the point of care. The test delivers results within 15 minutes from a pinprick with no instrumentation required. Health care professionals can use the results of the test, along with a patient’s medical history, symptoms, and results of another relevant testing, to make informed decisions about patient treatment and care.
March 25, 2020 - A study led by UnitedHealth Group Research & Development and OptumCare clinicians has demonstrated that a simple, self- collected test is as effective in identifying COVID-19 infections as the current clinician-collected test. The study found tests using self-administered swab tests accurately detected COVID-19 in more than 90% of positive patients, which is consistent with the clinician-administered test. The US FDA has updated its guidance based on the UnitedHealth Group research, allowing patients nationwide to self-administer swab tests for COVID-19.
March 24, 2020 - Q2 Solutions announced its collaboration with the University of Texas Medical Branch to develop a novel assay for COVID-19 (SARS-CoV-2) tests, an essential tool for the rapid development of a Coronavirus vaccine. Once a viable assay is developed, Q2 Solutions labs will produce it for use in clinical trials to determine the effectiveness of a COVID-19 vaccine.
March 23, 2020 - Heat Biologics, Inc. reported that it is collaborating with the University of Miami to develop a proprietary UM COVID-19 point-of-care diagnostic test. The new, patient-friendly test will require a simple pharyngeal throat swab to deliver on-the-spot results on a paper strip in under 30 minutes.
March 21, 2020 - Cepheid announced it has received Emergency Use Authorization from the U.S. Food & Drug Administration for Xpert® Xpress SARS-CoV-2, a rapid molecular diagnostic test for the qualitative detection of SARS-CoV-2, the virus causing COVID-19. The test has been designed to operate on any of Cepheid's more than 23,000 automated GeneXpert® Systems worldwide, with a detection time of approximately 45 minutes.
March 20, 2020 - Daxor Corporation announced the first use of its BVA-100 test to guide volume treatment in a patient infected with the COVID-19 virus. The company also announced the release of a clinical protocol for fluid guidance when utilizing the BVA-100 diagnostic test for COVID-19 patients. “The BVA-100 test has been shown in a prospective randomized control trial to reduce ICU mortality by as much as 66% and reduce ventilator days in populations suffering predominantly from respiratory distress and septic shock. In addition, we believe our test can have a significant impact on patient triage and help guide the precise administration of scarce resources such as ventilators"
March 19, 2020 - LabCorp announced that it will be able to perform more than 20,000 COVID-19 disease tests per day beginning March 20th. LabCorp is now performing COVID-19 testing at its labs in Phoenix, Ariz., Burlington, N.C., and Raritan, N.J.
March 18, 2020 - Abbott has received emergency use authorization from the FDA for its molecular test for the identification of SARS-CoV-2 coronavirus. The company is deploying 150,000 laboratory tests immediately in 18 states including Illinois, California, New York, Massachusetts, and Washington. Abbott is scaling up production at its U.S. manufacturing location to reach capacity for one million tests per week by end of March. The Abbott RealTime SARS-CoV-2 EUA test can be used on Abbott's molecular instrument, the m2000 RealTime System.
March 18, 2020 - Scientists from the University of Oxford’s Engineering Science Department and OSCAR have developed a rapid testing technology for the novel coronavirus SARS-CoV-2. The technology only requires a simple heat-block which maintains a constant temperature for RNA reverse transcription and DNA amplification, and the results can be easily read.
March 17, 2020 - Quest Diagnostics received emergency use authorization for its SARS-CoV-2 RNA, Qualitative Real-Time RT-PCR (“Quest SARS-CoV-2 rRT-PCR”) test for the qualitative detection of nucleic acid from SARS-CoV-2 in respiratory specimens from individuals suspected of COVID-19 by their healthcare provider.
March 16, 2020 - LabCorp announced it is rapidly expanding its 2019 Novel Coronavirus (COVID-19) testing capacity and expects the ability to perform more than 10,000 tests per day by the end of the week and 20,000 tests per day by the end of March. The LabCorp 2019 Novel Coronavirus (COVID-19), NAA test is available for ordering by physicians or other authorized healthcare providers anywhere in the USA.
March 16, 2020 - Thermo Fisher Scientific Inc. announced that on March 13, 2020, the U.S. FDA issued an emergency use authorization (EUA) for its diagnostic test that can be used immediately by CLIA high-complexity laboratories in the U.S. to detect nucleic acid from SARS-CoV-2, the virus that causes COVID-19 disease. The authorized test uses Applied Biosystems TaqPath Assay technology and is designed to provide patient results within four hours of a sample being received by a lab. The estimated time-to-result also includes time for sample preparation and instrument analysis.
March 13, 2020 - The US FDA authorized the Roche cobas SARS-CoV-2 Test, the third Emergency Use Authorization granted for a diagnostic test during the COVID-19 disease outbreak in the USA.
- March 13, 2020 - Thermo Fisher Scientific Inc. announced that the U.S. FDA has issued an emergency use authorization for its diagnostic test that can be used immediately by CLIA high-complexity laboratories in the U.S. to detect nucleic acid from SARS-CoV-2, the virus that causes COVID-19, and not for any other viruses or pathogens.
- March 12, 2020 - Co-Diagnostics, Inc. announced that Dr. Brent Satterfield Ph.D., Chief Scientific Officer and co-founder of Co-Diagnostics, will address a meeting held by the Bipartisan Commission on Biodefense in Washington, D.C. on March 18, 2020. Co-Diagnostics was the first U.S. company to receive a CE-mark for a COVID-19 diagnostic test. The Company is currently shipping orders for its test to countries on 5 continents, including shipments to Italy.
- March 12, 2020 - Twist Bioscience Corporation announced the availability of two synthetic SARS-CoV-2 RNA Controls. Positive controls provide quality control measures for the development, verification, and validation for diagnostic tests including both next-generation sequencings (NGS) and reverse transcription-polymerase chain reaction (RT-PCR) assays; determination of the limit of detection; and monitoring of day-to-day test variations.
- March 10, 2020 - LabCorp announced its LabCorp 2019 Novel Coronavirus (COVID-19), NAA test, is available today, beginning at 6 p.m. ET, for ordering by physicians or other authorized healthcare providers anywhere in the U.S. The test detects the presence of the underlying virus (SARS-CoV-2) that causes COVID-19 and is for use with patients who meet current guidance for evaluation of infection with COVID-19.
- March 10, 2020 – Premier Medical Laboratory Services announced their upcoming launch of Coronavirus (COVID-19) testing that will be available to hospitals and physician offices throughout the United States. Developed under CDC guidelines, PMLS’s COVID-19 test is undergoing FDA review for Emergency Use Authorization to begin testing patient samples as soon as validation is completed within the coming days.
- March 9, 2020 - The CDC issued an update to the Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 (COVID-19).
- March 8, 2020 - The CDC Health Alert Network Update CDCHAN-00429 highlights guidance and recommendations for evaluating and identifying patients who should be tested for COVID-19 that were shared on March 4, 2020, on the CDC COVID-19 website. It supersedes the guidance and recommendations provided in CDC’s HAN 428 distributed on February 28, 2020.
- March 7, 2020 - The University of Washington lab reports a 5-7% positivity rate. The UW SARS-CoV-2 assay is a one-step Real-Time RT-PCR assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal/oropharyngeal swabs. Results are for the identification of SARS-CoV-2 RNA. This University of Washington Department of Laboratory Medicine assay targets two distinct regions of SARS-CoV-2, the causative agent for COVID-19 disease, the RNA-dependent RNA polymerase gene and the E gene.
- March 6, 2020 - The CDC reported 72 state and local public health labs in 48 states and the District of Columbia have successfully verified and are currently using COVID-19 diagnostic tests. This CDC map includes states and territories with one or more laboratories that have successfully verified and are currently using COVID-19 diagnostic tests.
- March 5, 2020 - Texas Governor Greg Abbott announced that the state now has the capacity to test for COVID-19. Six public health labs within Texas' Laboratory Response Network are now equipped to perform COVID-19 testing, with the remaining four being fully equipped in the coming days.
- March 5, 2020 - On March 5, 2020, Insurance Commissioner Mike Kreidler issued an emergency order to Washington health insurers requiring them to waive copays and deductibles for any consumer requiring testing (www.doh.wa.gov) for coronavirus COVID-19 disease.
- March 5, 2020 - Quest Diagnostics announced it will launch a coronavirus (COVID-19) test service. The new test service aids the presumptive detection of nucleic acid in respiratory specimens of patients meeting CDC's clinical criteria for COVID-19 testing. The new test service will be provided as a laboratory-developed test, pending review by the FDA under emergency use authorization (EUA) which the company will submit per FDA guidance within 15 days of clinical testing. The test is a molecular-based assay that detects viral RNA in respiratory specimens.
- March 5, 2020 - California Orders Insurers To Waive Out-Of-Pocket Costs For Coronavirus Testing Amid Concerns Price Would Deter People: The California Department of Insurance and Department of Managed Health Care ordered all full-service commercial and Medi-Cal plans to “immediately reduce cost-sharing — including, but not limited to, co-pays, deductibles or coinsurance — to zero for all medically necessary screening and testing for COVID-19, including hospital, emergency department, urgent care and provider office visits where the purpose of the visit is to be screened and/or tested for COVID-19.”
- March 2, 2020 - Longhorn Vaccines & Diagnostics announced today that the U.S. FDA has recommended that the company collaborate with diagnostic assay manufacturers to ensure that Longhorn’s PrimeStore MTM® is included as a transport device in Emergency Use Authorization (EUA) applications submitted to the FDA for research samples for the Coronavirus disease 2019 (COVID-19). The suggestion comes in conjunction with key actions to advance the development of novel Coronavirus medical countermeasures outlined by the FDA’s US Center for Devices and Radiological Health.
February Coronavirus Diagnostic Development News
- February 29, 2020, the FDA issued a new policy for certain laboratories seeking to develop diagnostic tests for coronavirus in order to achieve more rapid testing capacity in the USA. The new policy is for certain laboratories that develop and begin to use validated COVID-19 diagnostics before the FDA has completed a review of their Emergency Use Authorization (EUA) requests. The FDA can issue an EUA to permit the use, based on scientific data. FDA Commissioner Stephen M. Hahn, M.D., said: “We are not changing our standards for issuing EUAs. This action today reflects our public health commitment to addressing critical public health needs and rapidly responding and adapting to this dynamic and evolving situation.”
- February 28, 2020 - The Chinese laboratory that first shared coronavirus genome with world ordered to close for ‘rectification’. No reason was given for the closure of the Shanghai facility, which released information about the virus ahead of authorities, reported SCMP.
- February 27, 2020 - Duke-NUS Medical School in Singapore researchers are among the front-runners to create a SARS-CoV-2 test, although its assay has to be validated before it is taken into production and deployed widely. The test was developed by a team led by Linfa Wang, an emerging disease specialist at Duke-NUS. In blood samples from recovered patients, the team identified antibodies targeting the spike protein that proved able to block the virus from killing cells in laboratory tests. In parallel, they created synthetic viral proteins that can detect those antibodies in a blood sample without having to use the live virus.
- February 26, 2020 - QIAGEN announces worldwide shipments of QIAstat-Dx test kits for SARS-CoV-2. QIAstat-Dx Respiratory 2019-nCoV Panel rapidly differentiates novel coronavirus from 21 other pathogens implicated in serious respiratory syndromes
- February 26, 2020, a study from China shows chest CT demonstrates better sensitivity than RT-PCR technique. Researchers at Tongji Hospital in Wuhan, China, concluded that CT should be used as the primary screening tool for COVID-19.
- February 25, 2020, Anitoa Systems demonstrated a solution for the rapid on-site nucleic acid test of the 2019 novel coronavirus (2019-nCoV). Anitoa combines a high performance ultra-portable Real-Time Polymerase Chain Reaction (qPCR) instrument called Maverick, with an innovative "one-step" reverse transcription qPCR (RT-qPCR) reagent for testing 2019-nCoV.
- February 21, 2020, a practical “how-to” protocol for healthcare and public health professionals” was published by the WHO. This protocol was designed to determine viable virus presence and persistence on fomites in various locations where a COVID-19 patient is receiving care or isolated, and to understand how fomites may play a role in the transmission of the virus.
- February 20, 2020, the CDC published a page including interim guidance and resources for laboratory professionals working with specimens from persons under investigation (PUI) for coronavirus disease 2019 (COVID-19).
- February 14, 2020, OSL started the dispatch of laboratory COVID-19 testing kits for 56 countries. As of 17 February, 37 shipments have been dispatched to 34 countries and 3 regional offices. Currently, the WHO says there are 15 laboratories identified to provide reference testing support for 2019-nCoV. The 2019-nCoV Realtime RTPCR test is reported to produce results in just 4 hours. On February 18, 2020, the WHO Situation Report #29 announced the WHO Operations Support and Logistics (OSL) continues to gather and assess the needs of Member States for critical items.
- February 4, 2020, the US FDA issued an emergency use authorization enabling the emergency use of the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel. This FDA authorization allows the use of the test at any CDC-qualified lab across the country. On February 5, 2020, the U.S. HHS announced the opening of an Easy Broad Agency Announcement for the development of 2019-nCoV diagnostics and is now accepting abstract submissions for potential funding. The diagnostics must utilize platforms already cleared by the U.S. FDA, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization within 12 weeks of an award.
- February 3, 2020 - Infection Prevention and Control Recommendations for Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) or Patients Under Investigation for 2019-nCoV in Healthcare Settings. This guidance is based on the currently limited information available about 2019-nCoV related to disease severity, transmission efficiency, and shedding duration.
> COVID-19 Antibody Test Now Available <
FDA Diagnostic Testing Information
NOTE: The information is sourced from organizations such as the CDC, NIH, WHO, and the Precision Vax news network and has been reviewed by Dr. Robert Carlson.